Spots Global Cancer Trial Database for Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer

Study Description

Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if capecitabine is more effective than vinorelbine in treating metastatic breast cancer. PURPOSE: Randomized phase II/III trial to compare the effectiveness of capecitabine with that of vinorelbine in treating women who have metastatic breast cancer that has been previously treated with chemotherapy.

Detailed Description: OBJECTIVES: Phase II Study: * Compare the response rate in women with previously treated metastatic breast cancer treated with capecitabine vs vinorelbine. * Compare the duration of response in patients treated with these drugs. Phase III Study: * Compare overall and progression-free survival in patients treated with these drugs. * Compare time to treatment failure in patients treated with these drugs. * Compare overall safety of these drugs in these patients. * Compare quality of life and clinical benefit response in patients treated with these drugs. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating center and taxane resistance (refractory vs resistant vs sensitive). * Phase II: Patients are randomized to 1 of 2 treatment arms. * Arm I: Patients receive vinorelbine IV on days 1 and 8. Courses repeat every 21 days. * Arm II: Patients receive oral capecitabine twice daily on days 1-14. Courses repeat every 21 days. In both arms, treatment continues in the absence of progression or unacceptable toxicity. If sufficient response rate is determined in phase II, the phase III study is initiated. * Phase III: Patients are randomized and receive treatment as in phase II. Quality of life is assessed prior to randomization, at weeks 3, 6, 9, 18, 24, and 30, and then every 12 weeks until disease progression. Clinical benefit response is assessed daily while patient is on study. Patients are followed every 6 weeks until disease progression and then every 12 weeks thereafter. PROJECTED ACCRUAL: A total of 72 patients (36 per treatment arm) will be accrued for phase II of this study and a total of 406-452 patients (203-226 per treatment arm) will be accrued for phase III of this study within 18.5 months.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Contact Details

Useful links and downloads for this trial